First Time Loading...

Kinnate Biopharma Inc
NASDAQ:KNTE

Watchlist Manager
Kinnate Biopharma Inc Logo
Kinnate Biopharma Inc
NASDAQ:KNTE
Watchlist
Price: 2.65 USD Market Closed
Updated: May 6, 2024

Kinnate Biopharma Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kinnate Biopharma Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Kinnate Biopharma Inc
NASDAQ:KNTE
Operating Income
-$119m
CAGR 3-Years
-49%
CAGR 5-Years
-73%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$8.7B
CAGR 3-Years
24%
CAGR 5-Years
1%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Kinnate Biopharma Inc's Operating Income?
Operating Income
-119m USD

Based on the financial report for Dec 31, 2023, Kinnate Biopharma Inc's Operating Income amounts to -119m USD.

What is Kinnate Biopharma Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-73%

Over the last year, the Operating Income growth was 0%. The average annual Operating Income growth rates for Kinnate Biopharma Inc have been -49% over the past three years , -73% over the past five years .